Chemomab Therapeutics
- Biotech or pharma, therapeutic R&D
No service providers meeting requests please (CRO, CDMO, Consultants and any other fee for service providers).
Chemomab (Nasdaq: CMMB) is a clinical-stage biotech developing innovative therapies for fibro-inflammatory diseases, focused on primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Our lead asset, Nebokitug, is a first-in-class anti-CCL24 mAb with strong clinical data. Following positive Phase 2 results in PSC, we are preparing for a Phase 3 trial. Nebokitug has FDA Fast Track and Orphan Drug designations and may be the first approved treatment for PSC. It is also Phase 2–ready for SSc and supported by a robust data package, with potential in additional fibrotic liver and lung indications. Learn more at chemomab.com.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}